ASPEN PHARMACARE HOLDINGS LIMITED - Further announcement regarding a commercialisation agreement with Astrazeneca in anaesthetics

Further announcement regarding a commercialisation agreement with Astrazeneca in anaesthetics

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
(“Aspen Holdings”)


FURTHER ANNOUNCEMENT REGARDING A COMMERCIALISATION AGREEMENT WITH ASTRAZENECA IN
ANAESTHETICS

Shareholders are referred to the announcement released by Aspen Holdings on 9 June 2016 wherein it was
stated that:

    -   Aspen Global Incorporated (“AGI”) had signed an agreement with AstraZeneca AB and AstraZeneca
        UK (“AstraZeneca”) whereby AGI will acquire the exclusive rights to commercialise AstraZeneca’s
        global (excluding the USA) anaesthetics portfolio (“the Transaction”); and

    -   subject to the fulfilment of customary closing conditions, the Transaction was anticipated to
        complete during the first quarter of Aspen’s 2017 financial year.

Aspen is pleased to confirm that the necessary closing conditions to the Transaction have been met and
that the Transaction, other than in respect of Ukraine and Zimbabwe which are subject to separate closing,
will be effective from today, 1 September 2016.

Durban
1 September 2016

Sponsor:
Investec Bank Limited

Date: 01/09/2016 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.